ROSELLA: A phase 3 study of relacorilant in combination with nab-paclitaxel versus investigator's choice in advanced, platinum-resistant, high-grade epithelial ovarian, primary peritoneal, or fallopian-tube cancer.

被引：0
|
作者：
Olawaiye, Alexander
Monk, Bradley J.
Herzog, Thomas J.
Copeland, Larry J.
Coleman, Robert L.
Moore, Kathleen N.
Randall, Leslie M.
Slomovitz, Brian M.
O'Malley, David M.
Eskander, Ramez Nassef
Pothuri, Bhavana
Van Gorp, Toon
Pignata, Sandro
Nicum, Shibani
Tudor, Iulia Cristina
Nguyen, Dorothy D.
Lorusso, Domenica
机构：
[1] Univ Pittsburgh, Pittsburgh, PA USA
[2] Creighton Univ Sch Med, Univ Arizona Coll Med, GOG Fdn, Phoenix, AZ USA
[3] Univ Cincinnati Canc Inst, Cincinnati, OH USA
[4] Ohio State Univ, James Canc Ctr, Columbus, OH USA
[5] US Oncol Res, Spring, TX USA
[6] Univ Oklahoma HSC, Stephenson Canc Ctr, Oklahoma City, OK USA
[7] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA USA
[8] Florida Int Univ, Mt Sinai Med Ctr, Miami Beach, FL USA
[9] Ohio State Univ, James Comprehens Canc Ctr, Columbus, OH USA
[10] Moores Canc Ctr, La Jolla, CA USA
[11] NYU Grossman Sch Med, Perlmutter Canc Ctr, NYU Langone Hlth, Ney York, NY USA
[12] Univ Hosp Leuven, Leuven Canc Inst, Leuven, Belgium
[13] Ist Nazl Tumori Napoli, Naples, Italy
[14] Univ Coll London Canc Inst, London, England
[15] Corcept Therapeut, Menlo Pk, CA USA
[16] Catholic Univ, IRCCS, Sacred Heart & Fondazione Policlinico Gemelli, Rome, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS5620
引用
收藏
页数：1
相关论文
共 50 条
  • [11] A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer
    Nagao, Shoji
    Kogiku, Ai
    Suzuki, Kazuhiro
    Shibutani, Takashi
    Yamamoto, Kasumi
    Jimi, Tomoatsu
    Kitai, Miho
    Shiozaki, Takaya
    Matsuoka, Kazuko
    Yamaguchi, Satoshi
    JOURNAL OF OVARIAN RESEARCH, 2020, 13 (01)
  • [12] A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer
    Shoji Nagao
    Ai Kogiku
    Kazuhiro Suzuki
    Takashi Shibutani
    Kasumi Yamamoto
    Tomoatsu Jimi
    Miho Kitai
    Takaya Shiozaki
    Kazuko Matsuoka
    Satoshi Yamaguchi
    Journal of Ovarian Research, 13
  • [13] Phase I study of weekly topotecan and gefitinib in patients with platinum-resistant ovarian, peritoneal, or fallopian tube cancer.
    Slomovitz, B. M.
    Coleman, R. L.
    Levenback, C.
    Jung, M.
    Gershenson, D. M.
    Wolf, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 278S - 278S
  • [14] Final results of a phase II trial of weekly nab-paclitaxel with GM-CSF as chemoimmunotherapy for platinum-resistant epithelial ovarian cancer.
    Swensen, Ron E.
    Goff, Barbara Ann
    Childs, Jennifer
    Higgins, Doreen
    Gooley, Theodore
    Fintak, Patricia A.
    Buening, Barbara
    Disis, Mary L.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [15] Phase I/II study of weekly topotecan and gefitinib in patients with platinum-resistant ovarian, peritoneal, or fallopian tube cancer.
    Chelariu-Raicu, Anca
    Levenback, Charles F.
    Slomovitz, Brian M.
    Bodurka, Diane C.
    Gershenson, David Marc
    Coleman, Robert L.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [16] A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer
    Berkenblit, A
    Seiden, MV
    Matulonis, UA
    Penson, RT
    Krasner, CN
    Roche, M
    Mezzetti, L
    Atkinson, T
    Cannistra, SA
    GYNECOLOGIC ONCOLOGY, 2004, 95 (03) : 624 - 631
  • [17] Phase II prospective study of weekly topotecan and bevacizumab in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer
    McGonigle, K. F.
    Muntz, H. G.
    Vuky, J.
    Paley, P. J.
    Veljovich, D. S.
    Gray, H. J.
    Malpass, T. W.
    GYNECOLOGIC ONCOLOGY, 2009, 112 (02) : S145 - S145
  • [18] Relacorilant plus nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer: Phase II subgroup analysis mirroring the patient population of an upcoming phase III study
    Colombo, N.
    Van Gorp, T.
    Matulonis, U. A.
    Oaknin, A.
    Grisham, R. N.
    Fleming, G.
    Olawaiye, A.
    Tudor, I. C.
    Pashova, H. I.
    Lorusso, D.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S793 - S793
  • [19] Relacorilant plus Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study
    Colombo, Nicoletta
    Van Gorp, Toon
    Matulonis, Ursula A.
    Oaknin, Ana
    Grisham, Rachel N.
    Fleming, Gini F.
    Olawaiye, Alexander B.
    Nguyen, Dorothy D.
    Greenstein, Andrew E.
    Custodio, Joseph M.
    Pashova, Hristina I.
    Tudor, Iulia C.
    Lorusso, Domenica
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (30) : 4779 - +
  • [20] A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group Study
    Coleman, Robert L.
    Brady, William E.
    McMeekin, D. Scott
    Rose, Peter G.
    Soper, John T.
    Lentz, Samuel S.
    Hoffman, James S.
    Shahin, Mark S.
    GYNECOLOGIC ONCOLOGY, 2011, 122 (01) : 111 - 115
12345